Neurocrine Biosciences, Inc.
NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
29 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$144.86
Price+0.48%
$0.69
1Y
Price
Market Cap
$14.403b
Large
Price/Earnings 3y Avg5y Avg
34.6x
Premium
Premium
Financials Overview
Key metrics over the past few years+37.7%
EBITDA Margin+26.4%
Net Profit Margin+27.0%
Free Cash Flow MarginRevenue
$2.683b
+13.9%
1y CAGR+21.8%
3y CAGR+24.2%
5y CAGREarnings
$428m
+25.4%
1y CAGR+41.2%
3y CAGR+49.0%
5y CAGREPS
$4.18
+27.1%
1y CAGR+39.5%
3y CAGR+47.0%
5y CAGRBook Value
$3.004b
$4.266b
Assets$1.262b
Liabilities$428.400m
DebtDebt to Assets
10.0%
0.6x
Debt to EBITDAFree Cash Flow
$593.100m
+6.4%
1y CAGR+24.2%
3y CAGR+27.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company